キメラ抗原受容体-マクロファージ（CAR-M）市場：ステークホルダー、技術、パイプライン、提携、資金調達

当レポートでは、世界のキメラ抗原受容体-マクロファージ（CAR-M）市場について調査し、市場の概要とともに、CAR-Mの技術評価、パイプラインと標的、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 単球とマクロファージの生物学

第4章 CAR-M情勢分析

• 企業評価
  • 会社概要
  • 融資
  • 提携
• CAR-M技術評価
  • 自家CAR-M技術
  • 同種CAR-M技術
• CAR-Mパイプライン、標的、および概念実証の評価

第5章 企業プロファイル

• Carisma Therapeutics
• CellOrigin Biotech
• Evotec
• Fate Therapeutics
• Inceptor Bio
• Myeloid Therapeutics
• Shoreline Biosciences
• Thunder Biotech

第6章 技術プロファイル

• ATAK CAR単球
• CAR-iMAC技術
• CAR-Mプラットフォーム
• iPSC CARマクロファージ（iMAC）技術

第7章 CAR-M細胞療法の候補プロファイル

• CT-0508
• CT-0525
• CT-1119
• MT-101
• MT-102
• MT-301
• MT-302

第8章 参考文献

Figures & Tables

Tables in the Text

• Table 1 Key Corporate Characteristics of Companies with CAR-M Technologies
• Table 2 Financing of Companies with CAR-M Technology
• Table 3 Product Partnering of CAR-M Companies
• Table 4 Technology and Manufacturing Partnering of CAR-M Companies
• Table 5 Overview of CAR-M Technologies at Carisma Therapeutics and Myeloid Therapeutics
• Table 6 Overview of Research Stage iPSC & CAR-iMac Technologies in Industry Development
• Table 7 CAR-M Pipeline: Targets, Constructs and R&D Stage
• Table 8 CAR-M Pipeline of Carisma Therapeutics
• Table 9 Myeloid Therapeutics' Pipeline of Product Candidates

This report provides you with a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023. CAR-M cell therapy is an approach to overcome the limitations and obstacles of CAR T-cell and CAR natural killer (NK) cell therapy. CAR-macrophages bring several unique benefits. CAR-macrophages can effortlessly submerge in the cancer environment. Additionally, CAR-macrophages can decrease the ratio of tumor-associated macrophages (TAMs) and switch the phenotype of TAMs. Moreover, CAR-macrophages play a phagocytic role in tumor cells, facilitate antigen presentation and augment the cytotoxicity of T cells. Finally, CAR-macrophages have less toxicity and limited circulation time than T cells.

Two main approaches for CAR-M cell therapy are:

Autologous CAR-M cell therapy with ex vivo manufacturing or in vivo engineering of monocytes;

Allogeneic CAR-M therapy based in induced pluripotent stem cells (iPSC).

The report brings you up-to-date with information about and analysis of:

Approaches for autologous and allogeneic CAR-m cell therapy;

Stakeholders in the field, i.e. technology companies, pharmaceutical partners and investors;

Technologies of CAR-M construction and manufacturing;

Delivery technologies: viral vectors; electroporation; lipid nanoparticles (LNPs)

Pipeline of autologous ex vivo/in vivo and allogeneic CAR-M cell therapy candidates;

Targets of CAR-M cell therapy candidates;

Proof-of-Concept with CAR-M cell therapy candidates;

Financing history and financial situation of CAR-M companies;

Partnering deals (discovery and/or development collaborations, licensing, acquisitions);

Comparative assessment.

Methodology:

This report is based on information retrieved for CAR-M technology companies and partner companies regarding discovery and development collaborations, technology in- and out-licensing and manufacturing arrangements. All information is fully referenced, either with scientific references (conference abstracts, Posters, presentations, full paper) or hyperlinks leading to the source of corporate information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles. For each CAR-M technology company, a profile has been elaborated providing information about the company background/history, the financial situation, relevant technology, partnering deals and target & pipeline overview.

Detailed description of CAR-M technologies from four companies is provided in the "CAR-M Technology Profiles" chapter. A general overview of CAR-M technologies from the other companies can be found in the respective company profile.

Eventually, this report has profiled seven CAR-M cell therapy candidates in preclinical and clinical stages of R&D. The descriptions can be found in the chapter "CAR-M Cell Therapy Candidate Profiles" in alphabetical order by the drug code.

A detailed CAR-M Industry Landscape Analysis precedes the three profile chapters with evaluations of the companies, CAR-M technologies and the CAR-M pipeline with targets and information about preclinical and clinical experience.

What will you find in the report?

Profiles of pure-play and diversified CAR-M technology companies;

Comprehensive description and analysis of emerging autologous and allogeneic CAR-M technologies;

Pharmacologic profiles of CAR-M cell therapy candidates;

Target selection, pipeline analysis and competition of CAR-M cell therapy candidates;

Description and analysis of financing rounds (capital raised, investors);

Economic terms of collaboration and licensing deals;

Sources of financing.

Who will benefit from the report?

Venture capital, private equity and investment managers;

Managers of Big Pharma venture capital firms;

Financial analysts;

Business development and licensing (BDL) specialists;

CEO, COO and managing directors;

Corporate strategy analysts and managers;

Chief Technology Officer;

R&D Portfolio, Technology and Strategy Management;

Clinical and preclinical development specialists;

Cell therapy specialists

Table of Contents

Table of Contents

Frequent Abbreviations

1 Executive Summary

2 Introduction

3 Monocyte and Macrophage Biology

4 CAR-M Landscape Analysis

• 4.1 Company Evaluations
  • 4.1.1 Corporate Overview
  • 4.1.2 Financing
  • 4.1.3 Partnering
• 4.2 CAR-M Technology Evaluations
  • 4.2.1 Autologous CAR-M Technologies
  • 4.2.2 Allogeneic CAR-M Technologies
• 4.3 Evaluation of CAR-M Pipeline, Targets and Proof-of-Concept

5 Company Profiles

• 5.1 Carisma Therapeutics
• 5.2 CellOrigin Biotech
• 5.3 Evotec
• 5.4 Fate Therapeutics
• 5.5 Inceptor Bio
• 5.6 Myeloid Therapeutics
• 5.7 Shoreline Biosciences
• 5.8 Thunder Biotech

6 Technology Profiles

• 6.1 ATAK CAR Monocytes
• 6.2 CAR-iMAC Technology
• 6.3 CAR-M Platform
• 6.4 iPSC CAR Macrophage (iMAC) Technology

7 CAR-M Cell Therapy Candidate Profiles

• 7.1 CT-0508
• 7.2 CT-0525
• 7.3 CT-1119
• 7.4 MT-101
• 7.5 MT-102
• 7.6 MT-301
• 7.7 MT-302

8 References

Tables in the Text